Anti-CD133抗体[293C3]

补充信息

This supplementary information is collated from multiple sources and compiled automatically.

CD133 also known as Prominin-1 is a transmembrane glycoprotein with a molecular weight of approximately 120 kDa. This protein stands out due to its expression in various stem and progenitor cells including those of the neural hematopoietic and epithelial lineages. CD133 is recognized for its distinct five transmembrane domains and two large extracellular loops. Researchers commonly use CD133 as a cell surface marker to identify stem and progenitor cells. The significance of CD133 extends to immunohistochemistry (IHC) and Western blot applications where it is a popular target for detection and analysis.

Biological function summary

CD133 is involved in maintaining the cellular architecture and signaling processes. It plays a role in cellular differentiation and proliferation while acting as a part of larger protein complexes on the cell surface. This protein is notable as it contributes significantly to the regulation of stem cell properties supporting the growth and repair in various tissues. Anti-CD133 antibodies are valuable tools in studying these functions due to their specificity in targeting this marker.

Pathways

CD133 participates in cellular signaling and transport pathways vital for intercellular communication and homeostasis. It interacts within pathways related to cell polarity and asymmetric division both essential for tissue development and maintenance. CD133 is associated with proteins like CD133/1 and CD133/2 which further highlights its involvement in these complex biological networks and on pathways such as the Wnt signaling pathway which regulates gene expression associated with cell proliferation and differentiation.

Several studies indicate a strong relationship between CD133 expression and certain cancers such as glioblastoma and colorectal cancer. In these cases CD133 serves not only as a marker but also as an indicator of the presence of cancer stem cells which are capable of tumor initiation and maintenance. Furthermore researchers have identified connections between CD133 and other proteins such as c-Met (cMab) within these pathological contexts suggesting interactions that could contribute to disease progression and offering potential targets for therapeutic intervention.